nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)

Background: The standard therapy for advanced stage non-small cell lung cancer (NSCLC) with no actionable gene alterations is a platinum-based chemotherapy doublet and immune checkpoint blocker (ICB), either concurrently or sequentially, followed by docetaxel at the time of tumor progression. Howeve...

Full description

Bibliographic Details
Main Authors: Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, Pieter E. Postmus, Jaafar Bennouna, Jürgen R. Fischer, Oscar Juan-Vidal, David J. Stewart, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Martin Reck, Denis Talbot, Ramaswamy Govindan, Teng Jin Ong
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
advanced stage non-small cell lung cancer
durvalumab
immune checkpoint blocker plus chemotherapy
nab-paclitaxel
second-line therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.569715/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.569715/full

Similar Items